FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
- Pfizer's gene therapy for a rare genetic bleeding disorder has received FDA approval, marking its first gene therapy clearance in the U.S.
- The treatment, named Beqvez, is priced at $3.5 million before insurance and rebates, positioning it as one of the most expensive drugs in the U.S.
- Beqvez, a one-time treatment, aims to help patients produce factor IX independently to manage bleeding in hemophilia B.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left2Leaning Right1Center7Last Updated11 days agoBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 20%
C 70%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage